Novo Nordisk to Launch Ozempic in India Ahead of Semaglutide Patent Expiry in 2026

Novo Nordisk has announced plans to launch its diabetes and weight management drug, Ozempic, in India. The move comes as the patents for semaglutide, the active ingredient in Ozempic, are set to expire in 2026. This development is expected to pave the way for increased competition in the Indian market, with domestic pharmaceutical companies preparing to introduce generic versions of the drug. Analysts anticipate that this competition could lead to reduced prices and broader access to GLP-1 receptor agonists, a class of drugs used for managing type 2 diabetes and obesity.

The impending patent expiration has prompted Indian drug manufacturers to gear up for entry into the market with their own formulations of semaglutide. Industry observers suggest that this could significantly alter the landscape of anti-diabetes and weight management treatments in India. Novo Nordisk’s decision to launch Ozempic ahead of this shift signals its intent to establish a strong foothold before generics become widely available. The introduction of these alternatives is likely to make such treatments more affordable and accessible across a wider segment of the population.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: September 30, 2025

Author

Mark Chiang